Retrospective analysis of anti-hepatitis c seropositive patients between 2018-2022

• DOI: 10.1016/j.jgar.2024.10.246
• Publication Date: 2024-12-26T04:16:33Z
• Authors: Firuze Soyak; Sevgi Özan Köse; Selda Sayın Kutlu; Murat Kutlu
• Keywords: Hepatitis C

Background: Determination of the clinical outcomes and epidemiological data of anti-HCV positive patients is crucial to management of Hepatitis C infection. METHODS: We retrospectively evaulated 340 patients who applied to our clinic and were found to be anti-HCV seropositive during five years period (2018-2022). RESULTS: Five of the patients (1,5%) had acute hepatitis C, 23 (6,8%) had spontaneous clearance, 102 (30%) patients had false positives anti-HCV result, and 210 (61.8%) patients had chronic Hepatitis C. The details of clininal and demographic findings were provided in Table 1. The frequency of chronic HCV infection was significantly higher in male patients, while the patients who had a false-posititive anti-HCV test were mostly women (p<0,001, p<0,001). Titer of anti-HCV antibody was meaningfully higher in chronic Hepatitis C patients compared to individuals who achived spontaneous clearance or had acute infection (p=0,001). Injecting drug use (IDU) was a major route of infection. Genotype 1b is the most prevalent genotype but genotype 2 and 3 becoming more prevalent in iv drug users. Sustained virologic response (SVR) was achieved in 99% of patients who achieved Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir combination and 100% of patients who received Glecaprevir/Pibrentasvir. CONCLUSIONS: Hepatitis C infection disproportionately affected male sex more than female, especially individuals who were ever incarserated. Anti-HCV levels were significantly different between the viremia and non-viremia patients and it seem to provide diagnostic performance for chronic Hepatitis C. Pan-genotypic treatment protocols should be used to achived SVR, especially in the regions have genetic diversity within HCV subtypes.